EDAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, EDAP TMS SA is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are positive developments in the company's business and financial performance, the lack of strong trading signals, mixed technical indicators, and a neutral sentiment in insider trading suggest that it is better to hold off on buying at this time.
The MACD histogram is positive at 0.0222 and expanding, indicating a potential upward trend. The RSI at 63.633 is in the neutral zone, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 3.631 and 3.768, with support levels at 3.188 and 3.051. Overall, the technical indicators are mixed, with no strong buy signal.
Hedge funds are significantly increasing their positions, with a 13044.55% increase in buying over the last quarter.
EDAP TMS is recognized as a leader in robotic energy-based therapies and medical device innovation.
The Focal One® system has strong adoption in Europe and the U.S., with potential for further expansion.
Insider trading sentiment is neutral, with no significant activity.
The stock has a 50% chance to decline in the short term (-2.81% in the next day, -2.56% in the next week, and -9.04% in the next month).
No recent congress trading data is available, indicating no influential political activity around the stock.
In Q4 2025, revenue increased by 1.00% YoY to $22,009,370.41. Net income improved significantly, up 369.96% YoY, but remains negative at -$9,507,537.49. EPS improved by 400.00% YoY to -0.25. While the company shows growth, it is still not profitable.
H.C. Wainwright analyst maintains a Buy rating but lowered the price target from $14 to $10, citing the company's progress in establishing high-intensity focused ultrasound as its core business and becoming a U.S. domestic filer. This indicates a positive long-term outlook but with tempered expectations.
